SCHEMBL1574496

SCHEMBL1574496

N#Cc1cccc(NC(=O)N2CC(N3CCN(c4ccc(OC(F)(F)F)cc4)CC3)C2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
GRIN2B Q13224 5/20 0.47
CCR2 P41597 1/20 0.45
NAMPT P43490 1/20 0.45
P2RY12 Q9H244 1/20 0.45
CYP2D6 P10635 3/20 0.45
HSD17B10 Q99714 1/20 0.45
USP2 O75604 4/20 0.45
CYP3A4 P08684 4/20 0.45
CYP1A2 P05177 4/20 0.45
TSHR P16473 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.45
LIPE Q05469 2/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
HIF1A Q16665 1/20 0.44
EPHX2 P34913 1/20 0.44
KIT P10721 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574468 0.89 KIT (0.52) GRIN2BNAMPTLIPECYP2C9CYP2C19
SCHEMBL1574555 0.87 MAPT (0.54) LMNAMAPTCYP2D6USP2CYP3A4
SCHEMBL1574951 0.86 LMNA (0.65) LMNAMAPTGRIN2BCCR2HSD17B10
SCHEMBL1574532 0.86 MAPT (0.50) LMNAMAPTGRIN2BUSP2CYP3A4
SCHEMBL1574999 0.86 EPHX2 (0.53) LMNAMAPTNAMPTLIPECYP2C9
SCHEMBL1574765 0.85 LMNA (0.59) LMNAMAPTGRIN2BNAMPTHSD17B10
SCHEMBL1574856 0.85 LMNA (0.48) LMNAMAPTHSD17B10USP2CYP3A4
SCHEMBL1575145 0.82 POLB (0.51) LMNAMAPTNAMPTLIPECYP2C9
SCHEMBL1574801 0.82 LIPE (0.51) LMNAMAPTLIPECYP2C9CYP2C19
SCHEMBL1574414 0.82 MAPT (0.55) LMNAMAPTP2RY12CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB LMNA 1076/4885MAPT 3908/4885GRIN2B 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.